Unfortunately, targeting of MEK1/MAPK1/2 signaling in clinical trials (219, 220) has not recapitulated the promising pre-clinical in vitro and in vivo studies that identified MEK1/MAPK1/2 as a molecular target to block breast cancer cell survival and progression (217, 221–223). Here, MAP2K1 is linked to breast carcinoma.